News Earnings Solara Active Pharma Q3FY26: ₹349 Cr Revenue, Strategic Review of Ibuprofen BusinessSolara Active Pharma Q3FY26: ₹349 Cr Revenue, Strategic Review of Ibuprofen Business
Solara Active Pharma Sciences delivered mixed Q3FY26 results with revenue growth to ₹349 crores but reported a net loss of ₹17.43 crores due to challenges in its ibuprofen business. The company's Growth API segment demonstrates strong profitability with 25% EBITDA margins, while the Base Ibuprofen business struggles with negative margins. The Board has appointed strategic advisors to evaluate options for the ibuprofen business and plans to convert the mothballed Vizag facility into a multipurpose plant.
*this image is generated using AI for illustrative purposes only.
Solara Active Pharma Sciences announced its Q3FY26 financial results, reporting revenue of ₹349 crores alongside a consolidated net loss of ₹17.43 crores. The pharmaceutical company's Board of Directors approved the unaudited financial results for the quarter ended December 31, 2025, during their meeting held on February 6, 2026. The company has engaged strategic advisors to evaluate options for its Ibuprofen business and reassess the previously announced CRAMS & Polymers business demerger.
Financial Performance Overview
The company's Q3FY26 results demonstrate revenue growth compared to the corresponding quarter of the previous year, with total income reaching ₹349 crores against ₹301.80 crores in Q3FY25. However, the company recorded a consolidated net loss of ₹17.43 crores, marking a significant shift from the ₹8.09 crores profit achieved in the same quarter last year.
| Financial Metric: | Q3FY26 | Q3FY25 | Change |
|---|---|---|---|
| Revenue from Operations: | ₹349.00 crores | ₹300.31 crores | +15% YoY |
| Total Income: | ₹349.00 crores | ₹301.80 crores | Growth |
| Net Loss/Profit: | Loss ₹17.43 crores | Profit ₹8.09 crores | Negative turnaround |
| Exceptional Item: | Loss ₹6.75 crores | - | New impact |
| EBITDA: | ₹37.40 crores | ₹59.10 crores | -37% YoY |
| EBITDA Margin: | 10.70% | 19.60% | -890 bps |
Strategic Business Transformation and Management Insights
During the earnings conference call held on February 6, 2026, management provided detailed insights into the company's strategic direction. Founder and Non-Executive Director Arun Kumar acknowledged the significant challenges facing the ibuprofen business, noting that Solara was historically the largest ibuprofen manufacturer globally. The company's Growth API business segment delivered strong performance with gross margins exceeding 55% and EBITDA margins of approximately 25%. In contrast, the Base Ibuprofen API business faced persistent headwinds with negative EBITDA margins of -22.90%.
| Business Segment: | Growth APIs Q3FY26 | Base Ibuprofen Q3FY26 |
|---|---|---|
| Revenue: | ₹246.60 crores | ₹102.40 crores |
| Gross Margin %: | 56.30% | 23.00% |
| EBITDA Margin %: | 24.70% | -22.90% |
Board Decisions and Strategic Review
The Board of Directors has appointed strategic advisors to evaluate options for the Ibuprofen business, recognizing the structural challenges and pricing pressures in the commodity segment. Management emphasized that the ibuprofen derivatives business remains profitable and is part of the growth segment. The board will also reassess the previously announced scheme for the CRAMS & Polymers business split, with management indicating that an integrated structure may provide more value. A comprehensive roadmap for both initiatives is expected to be presented in the subsequent quarter.
Operational Challenges and Future Plans
The company operates facilities in Pondicherry and Vizag with combined ibuprofen capacity of 10,000-12,000 tons, but current utilization is only around 3,000 tons. The Vizag facility has been mothballed, and management plans to convert it into a multipurpose plant including high potent API capabilities within the next 5-6 months. This transformation will require increased R&D investments and new talent acquisition to support the expanded product portfolio.
Nine-Month Performance Analysis
For the nine months ended December 31, 2025, Solara Active Pharma Sciences reported total income of ₹983.16 crores compared to ₹1,013.12 crores in the corresponding period last year. The company recorded a consolidated net loss of ₹17.01 crores for the nine-month period, contrasting with a profit of ₹2.64 crores in the previous year.
| Nine-Month Metrics: | FY26 (9M) | FY25 (9M) | Change |
|---|---|---|---|
| Total Income: | ₹983.16 crores | ₹1,013.12 crores | -3% YoY |
| Net Loss/Profit: | Loss ₹17.01 crores | Profit ₹2.64 crores | Negative shift |
| EBITDA: | ₹130.10 crores | ₹162.70 crores | -20% YoY |
| EBITDA Margin: | 13.20% | 16.10% | -290 bps |
Financial Position and Debt Management
The company continues its rights issue program, having raised ₹311.85 crores out of the total ₹449.95 crores rights issue as of December 31, 2025. Gross debt decreased to ₹630.00 crores from ₹776.00 crores, representing a 19% reduction. CFO Sarat Kumar indicated that ₹113 crores of debt reduction came from rights issue proceeds, while ₹33 crores was generated from operational cash flows. The expected gross debt by May 2026 is projected at approximately ₹499.90 crores.
Historical Stock Returns for Solara Active Pharma Sciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.07% | -2.25% | -10.64% | -26.79% | +2.52% | -62.26% |
19
